COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q study #73
Source   PDF   Share   Tweet
See all 151 studies
Early treatment study
Scholz et al., Preprints 2020, 2020070025, doi:10.20944/preprints202007.0025.v1 (Preprint)
COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxych loroquine and Azithromycin: A Retrospective Case Series Study
Early treatment with HC Q+AZ+Z results in 84% lower hospitalization and 80% lower death - hospitalization OR 0.16 (p<0.001), death OR 0.2 (p=0.16). No cardiac side effects. Retrospective 518 patients (141 treated, 377 control).
death, ↓79.4%, p=0.13
hospitalization, ↓81.6%, p<0.001
Source   PDF   Share   Tweet
See all 151 studies
Please send us corrections, updates, or comments.